Thirty-day rat toxicity study reveals reversible liver toxicity of mifepristone (RU486) and metapristone

Abstract

Objective: Mifepristone (RU486) is an oral first-line contraceptive used by hundreds of millions of women, and recently it was tested for anticancer activity in both genders worldwide. We are developing metapristone (the N-monodemethyl RU486) as a potential metastasis chemopreventive. The present acute and 30-d subacute toxicity study aimed at examining and compared in parallel the potential toxicity of the two drugs.

Methods: The single-dose acute toxicity and 30-d subacute toxicity studies were conducted in mice and rats, respectively, by gavaging metapristone or mifepristone at various doses. Blood samples and organs were collected for blood chemistry, hematology and histology analyses.

Results: Oral mifepristone (3000 mg/kg) caused 30% and 40% death in female and male mice, respectively, within 15 h post-dosing. In comparison, the same dose of metapristone produced 30% acute death in males only. Thirty-day oral administration of the two drugs to rats (12.5, 50 and 200 mg/kg/day) caused reversible hepatotoxicity that only occurred at 200 mg/kg/day group, evidenced by the elevated liver enzyme activity and liver organ weight.

Conclusion: The present study, for the first time, reveals reversible hepatotoxicity in rats caused by the 30-d consecutive administration at the high dose, and warns the potential hepatotoxicity caused by long-term administrations of high doses of mifepristone or metapristone in clinical trials but not by the acute single abortion doses.

• Acute toxicity
• liver toxicity
• metapristone
• mifepristone
• subacute toxicity

Declaration of interest

This research was financially supported by grants from the National Science Foundation of China No. 81273548 and No. 81502617, Fujian Development and Reform Commission 829054 (2014;168), the Ministry of Science and Technology of China No. 2015CB931804 and Natural Science Foundation of Fujian No. 2012J01406. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. The authors declare no conflict of interest.